Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. Social Networks
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. Hosting Providers
  14. CDN Services

We began analyzing https://stemcellres.biomedcentral.com/articles/10.1186/s13287-024-04127-y, but it redirected us to https://stemcellres.biomedcentral.com/articles/10.1186/s13287-024-04127-y. The analysis below is for the second page.

Title[redir]:
Mesenchymal stem cell therapy as a game-changer in liver diseases: review of current clinical trials | Stem Cell Research & Therapy | Full Text
Description:
Chronic liver diseases, including cirrhosis and liver failure, remain formidable challenges due to their complex progression and limited therapeutic options. Mesenchymal stem cell (MSC) therapy has emerged as a game-changing approach, leveraging its potent immunomodulatory, anti-fibrotic, and regenerative capabilities, along with the ability to transdifferentiate into hepatocytes. This review delves into the latest advances in MSC-based treatments for chronic and end-stage liver diseases, as highlighted in current clinical trials. MSCs derived from bone marrow and umbilical cord have shown remarkable promise in reversing liver damage, improving liver function, and providing hope for patients who do not respond to conventional therapies. When administered through hepatic, portal, or peripheral veins, MSCs have significantly improved liver histology, reduced fibrosis, and restored functional capacity. Furthermore, MSC-derived materials, such as extracellular vesicles and exosomes, are emerging as cutting-edge tools for treating liver failure and mitigating post-transplant complications. While autologous MSC-derived hepatocytes hold promise for non-fatal cirrhosis, allogeneic MSCs are being applied in more severe conditions, including liver failure and transplantation cases. Despite these promising early outcomes, larger trials and long-term studies are essential to fully harness MSCs as a transformative, off-the-shelf alternative to liver transplantation, heralding a new era in regenerative liver therapies.

Matching Content Categories {📚}

  • Science
  • Education
  • Health & Fitness

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🚀 Good Traffic: 50k - 100k visitors per month


Based on our best estimate, this website will receive around 50,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We can't tell how the site generates income.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Doi.org has a revenue plan, but it's either invisible or we haven't found it.

Keywords {🔍}

liver, pubmed, cells, article, google, scholar, stem, mesenchymal, cell, trials, cas, mscs, trial, cirrhosis, diseases, central, clinical, therapy, transplantation, failure, disease, patients, chen, msc, hepatic, wang, autologous, fibrosis, including, liu, zhang, allogeneic, treatment, chronic, million, human, function, hepatitis, ucmscs, bmmscs, table, immune, therapeutic, stromal, growth, phase, current, treating, complications, acute,

Topics {✒️}

adipose-derived stromal/stem cells decreasing tlr2/nf-kappab signaling myeloid-derived suppressor cell myeloid-derived suppressor cells hepatocyte growth factor/c-met umbilical cord-derived sources mesenchymal stromal/stem cells drug-induced liver injury end-stage liver disease mesenchymal stem cell-mediated end-stage liver diseases α-smooth muscle actin myeloid-derived suppressive phenotype placenta-derived multipotent cells monocyte-derived dendritic cells placenta-derived stem cells downregulating t-bet expression tri-service general hospital kynurenine-ahr-nrf2 pathway induce cd4 + cd25highfoxp3 + regulatory pi3k/akt/mtor pathway transforming growth factor-β1 utilizing cell-free products including anti-inflammatory cytokines biliary-specific inflammatory disease disease-related liver injury abo-incompatible liver transplantation cd4 + cd25 + foxp3 + regulatory mesenchymal stromal cells growth-regulated oncogene-γ [69] growth-regulated oncogene-γ inflammation-mediated liver diseases mesenchymal stem cell msc-derived prostaglandin e2 additional information publisher including bone marrow multipotent stromal cells growth-regulated oncogene chemokines vitro msc-mediated inhibition interleukin-1 receptor antagonist mesenchymal stem cells mesenchymal stem cells standard liver-supportive treatment increase il-10-expressing regulatory neutrophil-mediated tissue damage cell stem cell allogenic msc-based trials heme oxygenase-1-mediated induction egyptian hcv-positive patients hepatic transdifferentiation

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Mesenchymal stem cell therapy as a game-changer in liver diseases: review of current clinical trials
         description:Chronic liver diseases, including cirrhosis and liver failure, remain formidable challenges due to their complex progression and limited therapeutic options. Mesenchymal stem cell (MSC) therapy has emerged as a game-changing approach, leveraging its potent immunomodulatory, anti-fibrotic, and regenerative capabilities, along with the ability to transdifferentiate into hepatocytes. This review delves into the latest advances in MSC-based treatments for chronic and end-stage liver diseases, as highlighted in current clinical trials. MSCs derived from bone marrow and umbilical cord have shown remarkable promise in reversing liver damage, improving liver function, and providing hope for patients who do not respond to conventional therapies. When administered through hepatic, portal, or peripheral veins, MSCs have significantly improved liver histology, reduced fibrosis, and restored functional capacity. Furthermore, MSC-derived materials, such as extracellular vesicles and exosomes, are emerging as cutting-edge tools for treating liver failure and mitigating post-transplant complications. While autologous MSC-derived hepatocytes hold promise for non-fatal cirrhosis, allogeneic MSCs are being applied in more severe conditions, including liver failure and transplantation cases. Despite these promising early outcomes, larger trials and long-term studies are essential to fully harness MSCs as a transformative, off-the-shelf alternative to liver transplantation, heralding a new era in regenerative liver therapies.
         datePublished:2025-01-06T00:00:00Z
         dateModified:2025-01-06T00:00:00Z
         pageStart:1
         pageEnd:17
         license:http://creativecommons.org/licenses/by-nc-nd/4.0/
         sameAs:https://doi.org/10.1186/s13287-024-04127-y
         keywords:
            Mesenchymal stem cells (MSCs)
            Immunomodulation
            Anti-fibrosis
            Transdifferentiation
            Liver cirrhosis
            End-stage liver diseases
            Stem Cells
            Cell Biology
            Regenerative Medicine/Tissue Engineering
            Biomedical Engineering and Bioengineering
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13287-024-04127-y/MediaObjects/13287_2024_4127_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13287-024-04127-y/MediaObjects/13287_2024_4127_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13287-024-04127-y/MediaObjects/13287_2024_4127_Fig3_HTML.png
         isPartOf:
            name:Stem Cell Research & Therapy
            issn:
               1757-6512
            volumeNumber:16
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Wei-Chen Huang
               affiliation:
                     name:National Defense Medical Center
                     address:
                        name:Division of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
                        type:PostalAddress
                     type:Organization
                     name:National Defense Medical Center
                     address:
                        name:Laboratory of Clinical Immunology, National Defense Medical Center, Taipei, Taiwan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yuan-Chi Li
               affiliation:
                     name:Taipei Medical University
                     address:
                        name:School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Pin-Xuan Chen
               affiliation:
                     name:Taipei Medical University
                     address:
                        name:School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kevin Sheng-Kai Ma
               affiliation:
                     name:University of Pennsylvania
                     address:
                        name:Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Li-Tzu Wang
               affiliation:
                     name:Taipei Medical University
                     address:
                        name:School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
                        type:PostalAddress
                     type:Organization
                     name:Taipei Medical University
                     address:
                        name:Medical Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Mesenchymal stem cell therapy as a game-changer in liver diseases: review of current clinical trials
      description:Chronic liver diseases, including cirrhosis and liver failure, remain formidable challenges due to their complex progression and limited therapeutic options. Mesenchymal stem cell (MSC) therapy has emerged as a game-changing approach, leveraging its potent immunomodulatory, anti-fibrotic, and regenerative capabilities, along with the ability to transdifferentiate into hepatocytes. This review delves into the latest advances in MSC-based treatments for chronic and end-stage liver diseases, as highlighted in current clinical trials. MSCs derived from bone marrow and umbilical cord have shown remarkable promise in reversing liver damage, improving liver function, and providing hope for patients who do not respond to conventional therapies. When administered through hepatic, portal, or peripheral veins, MSCs have significantly improved liver histology, reduced fibrosis, and restored functional capacity. Furthermore, MSC-derived materials, such as extracellular vesicles and exosomes, are emerging as cutting-edge tools for treating liver failure and mitigating post-transplant complications. While autologous MSC-derived hepatocytes hold promise for non-fatal cirrhosis, allogeneic MSCs are being applied in more severe conditions, including liver failure and transplantation cases. Despite these promising early outcomes, larger trials and long-term studies are essential to fully harness MSCs as a transformative, off-the-shelf alternative to liver transplantation, heralding a new era in regenerative liver therapies.
      datePublished:2025-01-06T00:00:00Z
      dateModified:2025-01-06T00:00:00Z
      pageStart:1
      pageEnd:17
      license:http://creativecommons.org/licenses/by-nc-nd/4.0/
      sameAs:https://doi.org/10.1186/s13287-024-04127-y
      keywords:
         Mesenchymal stem cells (MSCs)
         Immunomodulation
         Anti-fibrosis
         Transdifferentiation
         Liver cirrhosis
         End-stage liver diseases
         Stem Cells
         Cell Biology
         Regenerative Medicine/Tissue Engineering
         Biomedical Engineering and Bioengineering
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13287-024-04127-y/MediaObjects/13287_2024_4127_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13287-024-04127-y/MediaObjects/13287_2024_4127_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13287-024-04127-y/MediaObjects/13287_2024_4127_Fig3_HTML.png
      isPartOf:
         name:Stem Cell Research & Therapy
         issn:
            1757-6512
         volumeNumber:16
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Wei-Chen Huang
            affiliation:
                  name:National Defense Medical Center
                  address:
                     name:Division of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
                     type:PostalAddress
                  type:Organization
                  name:National Defense Medical Center
                  address:
                     name:Laboratory of Clinical Immunology, National Defense Medical Center, Taipei, Taiwan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yuan-Chi Li
            affiliation:
                  name:Taipei Medical University
                  address:
                     name:School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Pin-Xuan Chen
            affiliation:
                  name:Taipei Medical University
                  address:
                     name:School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kevin Sheng-Kai Ma
            affiliation:
                  name:University of Pennsylvania
                  address:
                     name:Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Li-Tzu Wang
            affiliation:
                  name:Taipei Medical University
                  address:
                     name:School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
                     type:PostalAddress
                  type:Organization
                  name:Taipei Medical University
                  address:
                     name:Medical Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Stem Cell Research & Therapy
      issn:
         1757-6512
      volumeNumber:16
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:National Defense Medical Center
      address:
         name:Division of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
         type:PostalAddress
      name:National Defense Medical Center
      address:
         name:Laboratory of Clinical Immunology, National Defense Medical Center, Taipei, Taiwan
         type:PostalAddress
      name:Taipei Medical University
      address:
         name:School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
         type:PostalAddress
      name:Taipei Medical University
      address:
         name:School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
         type:PostalAddress
      name:University of Pennsylvania
      address:
         name:Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
         type:PostalAddress
      name:Taipei Medical University
      address:
         name:School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
         type:PostalAddress
      name:Taipei Medical University
      address:
         name:Medical Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Wei-Chen Huang
      affiliation:
            name:National Defense Medical Center
            address:
               name:Division of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
               type:PostalAddress
            type:Organization
            name:National Defense Medical Center
            address:
               name:Laboratory of Clinical Immunology, National Defense Medical Center, Taipei, Taiwan
               type:PostalAddress
            type:Organization
      name:Yuan-Chi Li
      affiliation:
            name:Taipei Medical University
            address:
               name:School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
               type:PostalAddress
            type:Organization
      name:Pin-Xuan Chen
      affiliation:
            name:Taipei Medical University
            address:
               name:School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
               type:PostalAddress
            type:Organization
      name:Kevin Sheng-Kai Ma
      affiliation:
            name:University of Pennsylvania
            address:
               name:Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
               type:PostalAddress
            type:Organization
      name:Li-Tzu Wang
      affiliation:
            name:Taipei Medical University
            address:
               name:School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
               type:PostalAddress
            type:Organization
            name:Taipei Medical University
            address:
               name:Medical Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Division of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
      name:Laboratory of Clinical Immunology, National Defense Medical Center, Taipei, Taiwan
      name:School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
      name:School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
      name:Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
      name:School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
      name:Medical Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan

Social Networks {👍}(2)

External Links {🔗}(624)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Prism.js

Emails and Hosting {✉️}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {📦}

  • Crossref

4.47s.